Effectiveness of oral iron chelator treatment with deferasirox in an aceruloplasminemia patient with a novel ceruloplasmin gene mutation

Intern Med. 2013;52(13):1527-30. doi: 10.2169/internalmedicine.52.0102. Epub 2013 Jul 1.

Abstract

A 59-year-old man presented with refractory anemia, choreoathetosis in the left upper extremity, an unsteady gait and cognitive dysfunction. The laboratory findings showed a marked decrease in ceruloplasmin. Magnetic resonance images revealed iron deposition in the brain and visceral organs. Iron accumulation was also observed in hepatocytes. Genetic analyses of the ceruloplasmin gene revealed a novel homozygous mutation of c.2185 delC in exon 12. The oral chelator deferasirox was effective in treating the left-side choreoathetosis and unsteady gait. Providing early treatment using deferasirox may be useful for preventing the progression of symptomatic neurological dysfunction.

Publication types

  • Case Reports

MeSH terms

  • Administration, Oral
  • Benzoates / administration & dosage*
  • Ceruloplasmin / deficiency*
  • Ceruloplasmin / genetics*
  • Deferasirox
  • Humans
  • Iron Chelating Agents / administration & dosage*
  • Iron Metabolism Disorders / diagnosis
  • Iron Metabolism Disorders / drug therapy*
  • Iron Metabolism Disorders / genetics*
  • Male
  • Middle Aged
  • Mutation / genetics*
  • Neurodegenerative Diseases / diagnosis
  • Neurodegenerative Diseases / drug therapy*
  • Neurodegenerative Diseases / genetics*
  • Treatment Outcome
  • Triazoles / administration & dosage*

Substances

  • Benzoates
  • Iron Chelating Agents
  • Triazoles
  • Ceruloplasmin
  • Deferasirox

Supplementary concepts

  • Familial apoceruloplasmin deficiency